Rheumatology Clinical Trials Institute Of Houston LLC is categorized under Medical Labs in Houston, TX and active since 2011.
Rheumatology Clinical Trials Institute Of Houston LLC was established in 2011, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Medical Labs business, which does work in the B2C market, and is classified as a Medical Labs, under code number 621511 by the NAICS.
If you are seeking more information, feel free to contact Michael Lesem at the company’s single location by writing to 1010 Waverly St, Houston, Texas TX 77008 or by phoning No number given. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Rheumatology Clinical Trials Institute Of Houston LLC |
| Contact Person: | Michael Lesem |
| Address: | 1010 Waverly St, Houston, Texas 77008 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2011 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Medical Labs |
| SIC Code: | 8071 |
| NAICS Code: | 621511 |
| Share This Business: |
Rheumatology Clinical Trials Institute Of Houston LLC was started in 2011 to provide professional Medical Labs under the SIC code 8071 and NAICS code 621511. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Michael Lesem for inquiries that concern Rheumatology Clinical Trials Institute Of Houston LLC by calling the company number No number given, as your correspondence is most welcome. Additionally, the physical location of the single location of Rheumatology Clinical Trials Institute Of Houston LLC can be found at the coordinates as well as the street address 1010 Waverly St in Houston, Texas 77008.
For its online presence, you may visit Rheumatology Clinical Trials Institute Of Houston LLC’s website at and engage with its social media outlets through on Twitter and on Facebook.